Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 7% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 4.4% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellcancerchemotherapydiseaseconcurrent
  Phrases that lowered it: relapsedthe efficacyevaluate theto evaluatepatients who
• Accepts healthy volunteers: No (raises risk) · Who can join
• Collaborators: 12 (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 190 (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past trials: 272 (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 24.4% (raises risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 96.4% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Responsible party: principal investigator (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 34146 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma NCT01980628 · started 2013 · scored riskier than 83% of active trials completed
• Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma NCT03846427 · started 2019 · scored riskier than 27% of active trials completed
• Bendamustine Hydrochloride in Combination With Rituximab in Patients With Relapsed Refractory Mantle Cell Lymphoma NCT00891839 · started 2009 · scored riskier than 89% of active trials completed
• A Study to Evaluate the Efficacy and Safety of Bendamustine Hydrochloride Injection NCT04569838 · started 2012 · scored riskier than 15% of active trials completed
• R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial NCT01133158 · started 2009 · scored riskier than 62% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.